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Abstract
Aim: The aim of this study was to identify potential predictive factors for cervical disease in women with HIV
and to evaluate adherence during follow-up to cervical cancer screening.
Methods: In order to identify the independent role of factors associatedwith the presence of a cervical abnormal-
ity, all of the variables showing in univariate analyses a potential association with the outcome variable (presence
of cervical abnormalities) were entered into amultivariate logistic regressionmodel, alongwith age at ﬁrst visit to
our center, and age at diagnosis.
Results: A total of 540 HIV-positive women who received screening for cervical cancer during the ﬁrst year after
their ﬁrst visit to our center were included in the analysis; 423 (78.3%) had normal cytology and 117 (21.7%) had
cytological abnormalities, classiﬁed as follows: 21 atypical squamous cells of undetermined signiﬁcance (17.9%);
51 low-grade squamous intraepithelial lesions (43.6%); 41 high-grade squamous intraepithelial lesions (35.0%);
and four cervical cancers (3.4%). In our study, women with more than two previous pregnancies were signiﬁ-
cantly associated with a lower risk of cervical cytological abnormalities compared to the other women. Women
with CD4+ levels of 200–499/mm3 had a higher risk of developing cervical cytological abnormalities compared
to those with a CD4+ level > 500/ mm3.
Conclusion: In summary, management of HIV-positive women must be modeled on HIV-clinical status, CD4+
cell count, drug regimen, and adherence to follow-up, relying on the cooperation of highly qualiﬁed professionals.
In HIV-positive women, an adequate screening and follow-up allows for a reduced occurrence of advanced cer-
vical disease and prevents recourse to invalidating surgical interventions.
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Introduction
Cervical cancer represents one of the most serious gyne-
cologic manifestations in women with HIV infection.1,2
Since 1993, the revised Centers for Disease Control and
Prevention AIDS case deﬁnition has included the devel-
opment of cervical cancer in anHIV-infectedwoman as a
sufﬁcient criterion for a clinical diagnosis of AIDS, even
in the absence of other opportunistic diseases.3 In HIV-
infectedwomen, there is an increased risk of humanpap-
illomavirus (HPV) infection and squamous
intraepithelial lesions (SIL), with an annual incidence
ﬁvefold higher than that of the general population
(8.3/100 women years vs 1.8/100 women years), and a
threefold increase in the risk of developing invasive cer-
vical cancer.4,5 Multiple prospective studies have
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demonstrated that women with HIV infection are much
more likely thanHIV-negative women to have persistent
HPV, often with oncogenic subtypes.6–8 Thus, compared
with HIV-negative women, HIV-positive women are
more likely to progress to cervical cancer, have a worse
prognosis, and are at higher risk of recurrence or persis-
tence.9,10 Prevention of cervical cancer relies on the de-
tection and treatment of SIL, a premalignant disease
stage.
The purpose of this study was to identify potential
predictive factors for cervical disease in women with
HIV and to evaluate adherence during follow-up to cer-
vical cancer screening guidelines in this particular group
of women.
Methods
This was a retrospective observational study. Screening
data from Papanicolaou (Pap) smears and colposcopic
examinations were collected in HIV-positive women
who attended the Center for STD and HIV/AIDS at
the Department of Obstetrics and Gynecology, Univer-
sity of Naples Federico II between January 2005 and
January 2010.
In addition to the standardized questionnaire, which
is given on admission to all of the women attending
our center and collects information on age, history of
STD, number of pregnancies, history of Pap smears,
number of sexual partners, country of origin, and ethnic-
ity, women with HIV were also evaluated for HIV route
of transmission, time from HIV diagnosis, possible illicit
drug abuse, HIV-related clinical events, and CD4+ cell
count (both determined in the 6 months preceding the
Pap smear and the colposcopic examination).
For each patient, we collected data from the Pap smear
and colposcopic examination, and recommended a
follow-up cytology evaluation after 6months forwomen
with CD4+ cell count < 200/mm3 and after 1 year for
women with CD4+ cell count> 500/mm3.11 Cytological
and histological samples were reviewed by the patholo-
gist of the Department of Biomorphological and Func-
tional Science, University Federico II of Naples.
Abnormalities on the Pap smear and biopsy results were
rated according to the Bethesda System classiﬁcation.12
Colposcopic examinations were performed by a
colposcopist, and the ﬁndings were rated according to
the International Federation of Cervical Pathology and
Colposcopy format (2007).13 To assess the adherence
(i.e. at least annually) of women with HIV to the screen-
ing program, the 5- and 10-year outcomes according to
the Italian Society of Colposcopy andCervical Pathology
guidelines (2006) were used.14
Statistical analysis was performed using SPSS ver. 19.0
(IBM Inc.) by a professional statistician (D.B.). Because
there were substantial missing data for the variables de-
scribing the partner’s HIV status and transmission route
(27.2%), amultiple imputation (MI) procedure was used.
Ten different complete datasets were generated using the
MI by chained equation algorithm. Due to the categori-
cal nature of the variable with missing information, a
polytomous regression model was used as the imputa-
tion model; all the study variables (Table 1)15 were en-
tered as covariates in the MI analysis.
Data were summarized as means (SD) for continu-
ous variables and as frequencies (%) for categorical vari-
ables. Univariate differences between the two groups
(women with or without any of the following cervical
abnormalities: atypical squamous cells of undetermined
signiﬁcance [ASCUS], low-grade squamous
intraepithelial lesions [LSIL], high-grade squamous
intraepithelial lesions [HSIL], and cervical cancer [CC]
on Pap smear) were assessed with the Student’s t-test
for independent samples in case of continuous variables
and with the χ2-test (or Fisher’s exact test if appropriate)
in case of categorical variables.
To identify the independent role of factors associated
with the presence of a cervical abnormality, all the vari-
ables showing in univariate analyses a potential associa-
tion (P < 0.25) with the outcome variable (presence of
cervical abnormalities) were entered into a multivariate
logistic regression model, along with age at ﬁrst visit to
our center, and age at diagnosis (Table 2).
Multiple logistic regression was based on MI of miss-
ing data. A sensitivity analysis based on available data
only gave highly consistent results (data not shown). As-
sociations between potentially predictive factors and the
outcome variable were reported as adjusted odds ratios
(AOR) with 95% conﬁdence intervals (CI).
Two-sided P-values < 0.05 were considered statisti-
cally signiﬁcant. All statistical analyses were conducted
using the statistical platform R ver. 2.12 (R Development
Core Team 2010).
Results
A total of 540HIVwomen received screening for cervical
cancer during the ﬁrst year after their ﬁrst visit to our
center and were therefore included in the analysis; 423
(78.3%) had normal cytology and 117 (21.7%) had cyto-
logical abnormalities, classiﬁed as follows: 21 ASCUS
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(17.9%); 51 LSIL (43.6 %); 41 HSIL (35.0%); and four cer-
vical cancers (3.4%). The main epidemiological and clin-
ical features of the women with and without cytological
abnormalities are summarized in Table 1. None of the
women included in the study had been vaccinated
against HPV.
In our study, women with more than two previous
pregnancies were signiﬁcantly associated with a lower
risk of cervical cytological abnormalities (odds ratio
[OR]: 0.50; 95% CI: 0.28–0.91; P = 0.022) compared to
other women. Patients with CD4+ levels < 200/ mm3
had a higher risk of developing cervical cytological ab-
normalities compared to those with a CD4+
level > 500/ mm3 (OR: 5.22; 95%CI: 2.55–10.69; P <
0.001). Women with CD4+ levels of 200–499/mm3 had
a higher risk of developing cervical cytological abnor-
malities compared to those with a CD4+
level > 500/mm3 (OR: 2.05; 95%CI: 1.05–3.98; P =
0.0035). Having ﬁve or more lifetime sexual partners
was also associated with an increased risk compared to
women with fewer than ﬁve lifetime sexual partners
(OR: 3.47; 95%CI: 2.55–10.69; P < 0.001).
During a mean follow-up of 4.5 years (range, 1–10
years) among the 423 women with a normal or benign
initial Pap smear, 183 (43.26%) did not receive cervical
cancer screening, one woman died of a drug overdose,
and 12 (2.83%) women were recently enrolled (between
2009 and 2010). Of the 183 women who did not repeat






(n = 117)† All (n = 540) P
Age at ﬁrst visit to our center (years) 33.3  7.2 33.8  8.0 33.4  7.4 0.52
Age at HIV diagnosis (years) 29.5  7.5 30.4  8.1 29.8  7.6 0.28
Smoking 120 (28.4%) 35 (29.9%) 155 (28.7%) 0.84
Geographic area of origin
Italy 299 (70.7%) 75 (64.1%) 374 (69.3%) 0.52
Eastern Europe 19 (4.5%) 7 (6.0%) 26(4.8%)
Africa 86 (20.3%) 29 (24.8%) 115 (21.3%)
Other (Western Europe, America, Asia) 19 (4.5%) 6(5.1%) 25 (4.7%)
Route of transmission of HIV
Heterosexual intercourse 315 (74.5%) 100 (85.5%) 415 (76.8%) 0.03
Drug abuse 94 (22.2%) 16 (13.7%) 110 (20.4%)
Other (blood transfusion, unknown,
vertical transmission, occupational
transmission)
14 (3.3%) 1 (0.8%) 15 (2.8%)
Previous pregnancies
0 110 (26.0%) 38 (32.5%) 148 (27.4%) 0.13
1–2 170 (40.2%) 46 (39.3%) 216 (40.0%)
>2 143 (33.8%) 33 (28.2%) 176 (32.6%)
CD4+ cell count/mm3
≥500 110 (26.0% 13 (11.1%) 123 (22.8%) <0.001
200–499 243 (57.4%)) 59 (50.4%) 302 (55.9%)
<200 70 (16.6%) 45 (38.5%) 115 (21.3%)
Antiretroviral therapy
None 224 (53.0%) 55 (47.0%) 279 (51.7%) 0.27
Mono- or dual NRTI therapy 112 (26.4%) 40 (34.2%) 152 (28.1%)
HAART 87 (20.6%) 22(18.8%) 109(20.2%)
Partner’s HIV status and transmission route‡
Heterosexual or transfused HIV-positive 180 (42.6%) 36 (30.8%) 216 (40.0%) 0.14§
Drug abuser HIV-positive 141 (33.3%) 48 (41.0%) 189 (35.0%)
HIV-negative 102 (24.1%) 33 (28.2%) 135 (25.0%)
Number of lifetime sexual partners
<5 272 (64.3%) 53 (45.3%) 325 (60.2%) P < 0.001
≥5 151 (35.7%) 64 (54.7%) 215 (39.8%)
†Of these 117 women, 21 had atypical squamous cells of undetermined signiﬁcance, 51 had low-grade squamous intraepithelial lesions, 41 had
high-grade squamous intraepithelial lesions, and four had cervical cancer. ‡Frequencies have been computed as unweighted average over the
10 complete datasets generated bymultiple imputation. §P-value was obtained according to the procedure described in Li et al.15 HAART, highly
active antiretroviral therapy; NRTI, Nucleoside reverse transcriptase inhibitors.
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Pap smears after the ﬁrst year, 68 (37.2%) were immi-
grants. Among the 423 patients with a normal benign
initial Pap smear, 227 (53.66) received Pap smears within
5 years after the ﬁrst visit and only 78 (18.43%) were
screened for cervical cancer with a Pap test 10 years after
their ﬁrst visit. Among the 124 immigrant women who
had a benign initial Pap smear, 68 (54.8%) did not repeat
their Pap smears during follow-up.
After a mean follow-up of 4.5 years, four
microinvasive cervical cancers and seven invasive cervi-
cal cancers occurred. Among these 11 patients with cer-
vical cancer, six (54.5%) women had never undergone a
Pap smear before their ﬁrst visit to our center and ﬁve
(45.5%) had had an interval of 4.2 (range, 2–5) years since
their previous Pap smear. Two of these ﬁve women had
had a normal cytology and three had had cytological ab-
normalities (two LSIL and one ASCUS). All of these 11
women were Italian; 10 (90.9%) of them had acquired
HIV through heterosexual contacts and one probably
through injection drug use (9.1%).
Discussion
One purpose of this study was to identify potential pre-
dictive factors for cervical disease in women with HIV.
Highly active antiretroviral therapy (HAART) has dra-
matically changed the natural history of HIV, increasing
CD4+ lymphocyte level, reducing the incidence of AIDS-
related disease and prolonging survival.16,17 The interac-
tions amongHIV,HPV,HAART, and the development of
cervical neoplasia are not clearly understood, and the
data on the impact of HAARTon incidence and severity
of cervical disease are often controversial. Data from
countries with adequate resources do not point to a clear
reduction in the burden and severity of cervical disease
following introduction of HAART, in contrast to other
AIDS-related malignancies (i.e. non-Hodgkin lym-
phoma).18–21 Conversely, in a study on 168 patients
treated with HAART, Heard observed a positive correla-
tion between regression of cervical lesions and improve-
ment of the immune system.22 Minkoff found a reduced
progression and increased regression of lesions.23 In our
study, the association between the variable antiretroviral
therapy and the presence of cervical cytological abnor-
malities was not assessed, as we did not enroll women
during the pre-HAART era.
Although the protective role of HAARTagainst cervi-
cal disease is controversial, there is more agreement on
the role of immunological status as a determinant factor
in the development of cervical intraepithelial neoplasia
among women with HIV.23–25 Our study conﬁrms the
higher risk associated with more advanced immune de-
terioration, as shown by the higher risk to develop SIL
among women with CD4+ levels< 200/mm3 compared
to women with CD4+ levels > 500/mm3 (OR: 5.22;
95%CI: 2.55–10.69; P < 0.001).
In agreement with previous studies conducted inter-
nationally,25–28 we also observed that a large number of
lifetime sexual partners (>5) was associated with an in-
creased risk of cervical abnormalities compared to
women with a number of lifetime sexual partners < 5
(OR: 3.47; 95%CI: 2.55–10.69; P < 0.001).
In contrast to claims made by the scientiﬁc litera-
ture,29–31 in our study,womenwithmore than two previ-
ous pregnancies were signiﬁcantly associated with a
lower risk of cervical cytological abnormalities (OR:
0.50; 95% CI: 0.28–0.91; P = 0.022) compared to other
women. A possible explanation for this result is that
women with a large number of children tend to be sexu-
ally more stable than others.
Another aim of this study was to determinate adher-
ence to the screening program and associations between
Table 2 Risk factors for presence of cervical lesions†
Adjusted odds
ratio (95%CI)‡ P
Route of transmission of HIV, n (%)
Heterosexual intercourse 1 —









1–2 0.65 (0.38–1.12) 0.119
>2 0.50 (0.28–0.91) 0.022
CD4+ cell count/mm3, n (%)
≥500 1 —
200–499 2.05 (1.05–3.98) 0.035
<200 5.22 (2.55–10.69) <0.001
Partner’s HIV status and transmission route†




HIV-negative 1.55 (0.78–3.09) 0.213
Number of lifetime sexual partners
<5 1 —
≥5 3.47 (2.55–10.69) <0.001
†Cervical lesions included: atypical squamous cells of undeter-
mined signiﬁcance, low-grade squamous intraepithelial lesions,
high-grade squamous intraepithelial lesions, and cervical cancer.
‡In addition to the variables reported above, odds ratios are
adjusted for age at ﬁrst visit to our center and age at diagnosis.
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demographic factors and receipt of Pap smear. Of 423
patients who had a normal or benign initial Pap smear,
227 (53.7%) continued receiving Pap smears during the
5-year follow-up, and only 78 (34.4%) women received
cervical cancer screening within 10 years. More than half
of the immigrant womenwith a benign initial Pap smear
did not repeat Pap smears during follow-up.
One potential explanation for these results is that these
women came from countries with no screening pro-
grams and limited resources for disease prevention.32
Of the 11HIV-positive womenwith cervical cancer, six
(54.5%) had never undergone a Pap smear before their
ﬁrst visit to our center, and ﬁve (45.45%) had had a time
interval between Pap smears of at least 4.2 years (range
2–5 years). As an AIDS-deﬁning illness, cervical cancer
poses a signiﬁcant but preventable risk to HIV-infected
women.32
The major limitation of our study is the retrospective,
single-center approach. Rates of intra- or inter-variability
of Pap smear reads and colposcopies were not deter-
mined. Examinations considering the oncogenic sub-
types of HPV were not carried out and nor was a
consideration of the association between cervical cancer
in HIV-infected women and socioeconomic status.
In summary, management of HIV-positive women
must be modeled on HIV-clinical status, CD4+ cell
count, drug regimen, and adherence to follow-up, rely-
ing on the cooperation of highly qualiﬁed professionals.
In HIV-positive women, an adequate screening and
follow-up allows for a reduced occurrence of advanced
cervical disease and prevents the recourse to
invalidating surgical interventions.
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